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Background: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD).
Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active
CD, several other scenarios involve a need for additional blood-based CD markers.
Methods: We investigated the levels of messenger RNA (mRNA) in whole blood (n = 49) and protein in plasma
(n = 22) from cases with active CD (n = 20), with confirmed CD and normalized histology (n = 15), and without a
CD diagnosis (n = 14). Group differences were analyzed using Kruskal-Wallis one-way analysis of variance by ranks.
We also investigated correlations between levels of potential markers, histopathology according to the modified
Marsh scale, and CD risk gradient based on HLA type, using Spearman rank correlation. The relation between
HLA-DQ2 gene dose effect and the expression levels of selected blood-based markers was investigated using the
Mann–Whitney U test. Finally, the diagnostic performance of anti-TG2, potential blood-based CD markers, and
logistic regression models of combined markers was evaluated using receiver operating characteristic (ROC)
curve analysis.
Results: CXCL11 protein levels and TNFRSF9 and TNFSF13B mRNA levels were identified as potential CD
markers. These are all affected by or involved in the regulation of the NF-κB complex. CXCL11 protein levels
and IL21 and IL15 mRNA levels were correlated with histopathology according to the modified Marsh scale,
as were the established CD markers. HLA genotype risk and HLA-DQ2 gene dose effect did not show any
significant relations with either the potential CD markers or the established CD markers. ROC curve analysis
revealed a slight, non-significant increase in the area under the curve for the combined use of anti-TG2 and
different constellations of potential blood-based CD markers compared to anti-TG2 alone.
Conclusions: The CD markers identified in this study further emphasize the significance of components related to
NF-κB regulation in relation to CD. However, the relevance of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB interacting
proteins recognized by pathway analysis, needs to be further investigated in relation to diagnosis and monitoring
of CD.
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Celiac disease (CD) is defined as a “chronic small intestinal
immune-mediated enteropathy precipitated by exposure to
dietary gluten in genetically predisposed individuals” [1].
Autoantibodies against tissue transglutaminase (TG2) can be
found in the blood, as can antibodies against endomysium,
deamidated gliadin (DGP), and native gliadin (GL); and infil-
tration of intraepithelial lymphocytes (IELs) in the epithe-
lium, elongation of the crypts, and destruction of villi is seen
in the small intestine [2]. A strong genetic component is* Correspondence: hanna.gustafsson.bragde@lj.se
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unless otherwise stated.evident in CD, with the strongest association found in
the HLA region [3,4], primarily with DQ2 (DQA1*05/
DQB1*02) and in a minority of CD patients with DQ8
(DQA1*0301/DQB1*0302) [5,6]. There is a gene dose
effect of HLA-DQ2 [7], and risk gradients based on HLA
type have been calculated [8,9]. A number of other risk
loci containing multiple candidate genes have been associ-
ated with CD [3,4,10-12].
Current CD diagnostics primarily include antibody de-
tection, mainly of Immunoglobulin A (IgA) autoantibodies
against TG2 (anti-TG2), and confirmation of the diagnosis
by histopathologic assessment of small intestinal biop-
sies [13]. The European Society of Paediatric Gastroenter-
ology, Hepatology and Nutrition (ESPGHAN) WorkingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that children and adolescents with clear symptoms and
anti-TG2 levels over 10 times the upper limit of normal
(ULN), with a remission of symptoms on a gluten-free
diet (GFD), could be diagnosed with CD without histo-
pathologic assessment of an intestinal biopsy [14]. Add-
itionally, the presence of HLA-DQ2 or DQ8 should be
verified.
We have previously developed a discriminant analysis
model based on gene expression data in duodenal biop-
sies. This model can discriminate between biopsies with
and without histopathologic alterations indicative of CD,
and also indicate the level of histologic damage as well
as mucosal recovery on a GFD [15]. The identification of
blood-based markers which could reinforce the diagnos-
tic value of anti-TG2, and perhaps indicate the level of
histologic damage and mucosal recovery on GFD, would
further simplify CD diagnostics.
In the present study, we investigated levels of candidate
CD markers (messenger RNA [mRNA] and protein) in
blood from celiac and non-celiac cases, and considered
the possible added value of these candidate markers. We
also explored the relations between candidate markers
and enteropathy graded according to the modified Marsh
scale [16], CD risk gradient based on HLA type [8], and
HLA-DQ2 gene dose effect [7].
Methods
Study subjects and samples
Following written informed consent from parents/legal
guardians, blood and duodenal biopsy specimens were
collected from pediatric patients (Table 1) investigated
for suspected CD or at follow-up on a gluten-free or
gluten-containing diet, both for diagnostic purposes and
for research purposes.Table 1 Descriptive data on study subjects including clinical a






Not CD 14 (8) 8.8; 2.2-16 Marsh 0-1
Normalized CDf 15 (13) 12; 7.3-17 Marsh 0-1
Active CDg 20 (12) 5.9; 1.5-14 Marsh 2-3
Under investigationh 3 (3) 15; 12-16 Marsh 0-1
Study subjects are divided into groups depending on the diagnosis and the histopa
aInitially, a total of 56 cases were included in the study, but three cases were later e
histopathologically non-assessable biopsies, leaving 52 cases included in the analys
bCR = Central range.
cTissue transglutaminase autoantibodies (anti-TG2), positive result ≥ 7 U/mL.
dDeamidated gliadin antibodies (anti-DGP), positive result ≥ 10 U/mL.
eGliadin antibodies (anti-GL), positive result ≥ 7 U/mL.
fCases with confirmed celiac disease and duodenal biopsies indicating a Marsh grad
cases had suboptimal (but assessable) biopsies.
gCases with duodenal biopsies indicating a Marsh grade 2-3C, on a gluten-containin
small intestine.
hCases under continued gluten challenge and observation due to elevated antibod
and maximum values.For diagnostic purposes, blood was collected in a blood
tube containing polymer gel and clot activator (Becton,
Dickinson and Company, Franklin Lakes, NJ) and centri-
fuged at 2400 × g for 5 min for serum isolation. The sera
were stored at room temperature for a maximum of
10 hours after centrifugation, and then at 4°C until the
presence of CD-specific antibodies (anti-TG2 and anti-
bodies against DGP [anti-DGP]) and antibodies against
GL (anti-GL) was investigated, which occurred within
5 days of centrifugation. In six cases, the antibody tests
were performed on plasma collected for research pur-
poses. Multiple biopsy specimens were collected using an
endoscope in all but one case, where a pediatric Watson
capsule was used to extract a single biopsy specimen. The
tissue was formalin-fixated and paraffin-embedded, and
histopathologically assessed.
For research purposes, blood was collected both in
EDTA blood tubes (Becton, Dickinson and Company)
for DNA and plasma isolation, and in Tempus Blood
RNA tubes (Life Technologies, Carlsbad, CA) for RNA
isolation. An aliquot of EDTA blood for DNA isolation
was removed, and the remaining blood centrifuged at
1500 × g for 10 min for plasma isolation. For two cases,
one in the group with no indications of CD and one in
the group with active CD (Table 1), blood for RNA puri-
fication was collected in EDTA blood tubes instead of
Tempus tubes. Additionally, a biopsy specimen immersed
in pre-chilled RNAlater RNA Stabilization Reagent
(Qiagen, Hilden, Germany) was collected from all cases
in the study. Biopsies and stabilized blood for RNA purifi-
cation were kept at 4°C for about 18 hours, and then
at −20°C. RNA from EDTA blood was, however, puri-
fied without prior storage. Plasma was stored at −80°C. A








0.25; 0.05-11 0.95; 0.20-20 0.60; 0.10-2.4
3.4; 0.40-28 2.6; 1.2-9.3 0.80; 0.20-4.1
C 201; 4.4-1997 64; 5.6-392 16; 2.4-167
15; 10-16 7.1; 2.1-22 1.9; 0.50-6.5
thologic assessment.
xcluded due to low sample amount and one case was excluded due to
es.
e 0–1, on a gluten-containing diet (n = 1) or a gluten-free diet (n = 14). Two
g diet (n = 18) or a gluten-free diet (n = 2). One case had patchy lesions of the
y titers but normal mucosa. Ranges for this group are represented by minimum
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Regional Ethical Review Board in Linköping.DNA purification
DNA was isolated from EDTA blood using the EZ1 DNA
Blood 350 μL Kit and BioRobot EZ1 (Qiagen) according
to the manufacturer’s instructions.RNA purification and reverse transcription
RNA from stabilized blood was purified using the Tempus
Spin RNA Isolation Reagent kit (Life Technologies), and
RNA from EDTA blood was purified using the QIAamp
RNA Blood Mini kit (Qiagen), in both cases according to
the manufacturer’s instructions. The quality of the RNA
from stabilized blood and EDTA blood was verified, and
the RNA was reverse transcribed using a previously docu-
mented procedure [15]. The resulting cDNA and the
remaining RNA were stored at −80°C.Histopathologic assessment
Biopsies were assessed by a single experienced pathologist,
blinded to all case data, in accordance with instructions
for quality assurance and standardization assembled by
the Swedish Society of Pathology. The status of the villi and
crypts and the number of IELs were assessed for each bi-
opsy. In cases where hematoxylin-eosin staining revealed
an IEL number close to the ULN (25 IELs per 100 epithelial
cells), an additional staining for CD3 was performed to bet-
ter assess the number of IELs; when using CD3 staining,
there should be >30 IELs per 100 epithelial cells to be in-
dicative of CD. Hematoxylin-eosin staining was performed
using the Tissue-Tek DRS 2000 Slide Stainer (Sakura,
Alphen aan den Rijn, The Netherlands), and CD3 staining
was performed using antibodies against CD3 (Dako, Glostrup,
Denmark) and intelliPATH FLX (Biocare Medical, Concord,
CA). The histological changes were reported according to
the modified Marsh scale (0, 1, 2, 3A, 3B, or 3C) [16].Clinical antibody tests
Detection of IgA anti-TG2, IgA anti-GL, and Immuno-
globulin G (IgG) anti-DGP in serum or plasma was per-
formed using EliA Celikey IgA (positive result ≥ 7 U/mL),
EliA Gliadin IgA (positive result ≥ 7 U/mL), and EliA
GliadinDP IgG (positive result ≥ 10 U/mL), respectively,
on Phadia250 (Thermo Fisher Scientific, Waltham, MA)
as described by the manufacturer. In cases with total IgA
levels below 0.07 g/L, detection of IgG anti-TG2 replaced
IgA anti-TG2 (EliA Celikey IgG, Thermo Fisher Scientific).
In order to distinguish results below the detection limit of
an assay from missing data, the former were replaced with
the detection limit divided by two.HLA typing and risk assessment
DNA from each case was HLA-typed for DRB1, DQA1
and DQB1 using a sequence-specific primer PCR method
and capillary gel electrophoresis [17,18]. The risk gradient
for CD based on HLA type was calculated for each case
using relative genotype risks extracted from a Scandi-
navian population [8].
Selection of genes for analysis
Potential reference genes for the mRNA analysis were
investigated using a Human Endogenous Control Plate
(Life Technologies) containing assays for 32 potential ref-
erence genes, and cDNA from a total of nine blood RNA
samples including three samples from cases with no mu-
cosal injury (Marsh 0) and six with varying degrees of mu-
cosal injury (Marsh 2-3C). Three potential reference genes
(Additional file 1) were selected based on low sample-to-
sample variation in mRNA levels, as investigated using the
NormFinder algorithm [19] in version 5.4.2 of the Genex
software package (MultiD Analyses, Göteborg, Sweden).
The three selected reference genes were analyzed in the
complete dataset, and the final selection of reference gene/s
was established using the complete dataset by means of
both low sample-to-sample variation and an absence of
group differences in expression.
Genes for analysis of mRNA and protein levels were
selected by reviewing published studies on blood mRNA/
protein expression in CD, and by functional context
(Additional file 1).
Protein analysis
Multiplex detection of proteins in plasma was performed
using Milliplex kits (Millipore, Billerica, MA) based on the
Luminex xMAP technology, according to the manufac-
turer’s instructions (Additional file 1). The analyses were
performed on the Bio-Plex 200 system (Bio-Rad, Hercules,
CA). The CD163 soluble protein was detected using an
enzyme-linked immunosorbent assay (ELISA) according
to instructions from the manufacturer (Additional file 1),
and the results were obtained and analyzed using a
Sunrise microplate absorbance reader combined with ver-
sion 7.0 of the Magellan software package (Tecan Group
Ltd, Männedorf, Switzerland). Standard curves were
included in all protein analyses, and optimized using
Bio-Plex Manager 6.1 (Bio-Rad) for all Milliplex assays,
and the Akima method for curve fitting in Magellan v.7.0
for the ELISA. In order to distinguish results below the
detection limit of an assay from missing data, the former
were replaced with the lowest detected value of the assay
divided by two.
mRNA analysis
Levels of mRNA were investigated using custom made
TaqMan Array Cards (Life Technologies) containing 47
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genes, or by using single assays and a previously docu-
mented procedure [15] (Additional file 1). Gene expression
analysis on the TaqMan Array Cards was performed using
the TaqMan Universal Master mix II without UNG and
the recommended thermal profile (Life Technologies) on
300 ng cDNA in duplicates. Cards were prepared as rec-
ommended by the manufacturer, including analysis on the
7900HT Fast Real-time PCR system (Life Technologies).
For both TaqMan Array Cards and single assay results,
quantification cycle (Cq) values were established using
version 1.0.2 of the ExpressionSuite software package
(Life Technologies). The auto-baseline algorithm in the
software was used to compensate for background noise
for each amplification curve, and the thresholds were
adjusted to the log-linear range and set to the same level
for all samples within one assay. Missing Cq values due
to low copy numbers were replaced by the highest Cq
value available for the gene in question, increased by one
cycle. The resulting Cq values were normalized against
selected reference gene/s (Genex).
Statistical analysis
Version 10 of the STATISTICA software package
(StatSoft, Tulsa, OK) was used in all statistical analyses.
Differential expression was investigated using Kruskal–
Wallis one-way analysis of variance by ranks, except for
the analysis of differential expression in cases stratified
based on having one or two DQB1*02 alleles, where the
Mann–Whitney U test was used. Post-hoc comparisons of
mean ranks of all pairs of groups were performed (signifi-
cance level p < 0.05, two-sided significance levels with a
Bonferroni adjustment) [20]. Spearman rank correlation
was used to investigate relations between mRNA/protein
levels and histopathology and CD risk gradient based on
HLA type. For all statistical analyses, except the post-hoc
comparisons, a false-discovery rate was used and set
to 5% [21].
The diagnostic performance of individual assays and lo-
gistic regression models of assay combinations was evalu-
ated using receiver operating characteristic (ROC) curve
analysis (MedCalc Statistical Software version 13.1.2,
MedCalc Software, Ostend, Belgium).
Results
Differential blood marker expression
Detectable levels were found for all protein markers
(n = 22, Additional file 1), and all mRNA markers except
for IL25 (n = 48, Additional file 1). CDKN1B was selected as
the most stable reference gene, and used for normalization
of all target mRNA levels.
In cases with active CD (Table 1, Active CD), signifi-
cantly increased levels were observed for CXCL11 protein
(p = 0.003, Figure 1, Additional file 2) and TNFSF13BmRNA (p = 0.001, Figure 1, Additional file 2), in compari-
son to cases without a CD diagnosis (Table 1; Not CD).
Additionally, TNFSF13B mRNA levels were significantly
elevated in cases with confirmed CD and normalized hist-
ology (Table 1; Normalized CD), in comparison to cases
without a CD diagnosis (p = 0.001, Figure 1, Additional
file 2). Levels of TNFRSF9 mRNA were significantly
decreased in cases with active CD and in cases without a
CD diagnosis, in comparison to CD cases with a normal-
ized histology (p = 0.005 and p = 0.02, respectively,
Figure 1, Additional file 2).
Previously established CD markers (anti-TG2, anti-
DGP, and anti-GL) were differentially expressed in active
CD cases in comparison to cases with normalized CD
(p < 0.005) as well as cases without a CD diagnosis (p <
0.00005).
Stratification based on having one or two DQB1*02
alleles revealed no significant differences in levels of po-
tential CD markers or in levels of previously established
CD markers (anti-TG2, anti-DGP, and anti-GL), either
when examining active CD cases only, or when looking
at all CD cases together. Differences in expression in
normalized CD cases alone could not be investigated,
because all but two cases had one DQB1*02 allele.Correlation analysis
Significant correlations were observed between Marsh
grade (all cases) and levels of CXCL11 protein (Figure 2;
Spearman rank correlation coefficient [rs] = 0.50), and IL21
and IL15 mRNA (rs = −0.46 for both, data not shown).
Clinical antibody levels (anti-TG2, anti-DGP, and anti-
GL) displayed significant correlations with Marsh grade
(rs = 0.73, 0.75, and 0.75, respectively; Figure 3).
Levels of potential and previously established CD markers
were not significantly correlated with HLA genotype risk
for CD.Clinical antibody tests
All cases on a gluten-containing diet with anti-TG2 levels
10 times ULN or more (n = 13) showed a Marsh grade of
3A-3C and received a CD diagnosis. Correspondingly high
levels of anti-DGP (n = 7) and anti-GL (n = 4) were less
common, but all occurred in cases with an active CD
diagnosis and a Marsh grade 3A-3C.
Of all cases with active CD on a gluten-containing diet
(n = 18) and all cases without CD diagnosis (n = 14), anti-
TG2 failed to identify one case with active CD (Marsh 3C,
anti-TG2 3.4 U/mL) and gave a false positive result in
two cases without CD diagnosis (Marsh 0–1, anti-TG2
11–23 U/mL).
Anti-DGP yielded the same number of misclassifications
as anti-TG2, but affected partially different cases, whereas
anti-GL yielded substantially more misclassifications with
































































Figure 1 Protein/messenger RNA (mRNA) levels of potential celiac disease (CD) markers. Levels of (A) CXCL11 protein, (B) TNFRSF9 mRNA,
and (C) TNFSF13B mRNA in cases without a CD diagnosis (Not CD), cases with confirmed CD and normalized duodenal histology (Normalized
CD), and cases with active CD (Active CD). The box and the line represent the 25-75% interquartile range and the median, respectively. The
whiskers represent the non-outlier range, open circles represent outliers, and stars represent extreme values.
Bragde et al. BMC Gastroenterology 2014, 14:176 Page 5 of 9
http://www.biomedcentral.com/1471-230X/14/176four false negative results, and one false positive result
(data not shown).
Two cases with remaining enteropathy on a GFD (Marsh
2 - 3A, anti-TG2 2.0 - 5.4 U/mL) had normalized levels of
all antibodies.
Misclassified cases and cases under clinical investigation
The case with active CD on a gluten-containing diet that
was misclassified based on levels of anti-TG2 (see Clinical
antibody tests) showed levels of the two CD up-regulated
markers CXCL11 protein and TNFSF13BmRNA (Figure 1)
























Figure 2 CXCL11 protein levels vs. Marsh grade. CXCL11 protein levels f
3C (n = 5). The box and the line represent the 25-75% interquartile range a
range, open circles represent outliers, and stars represent extreme values.without CD and within the 80% CR for the group with
active CD (Additional file 2). For one of the two cases
without CD that were misclassified based on levels of
anti-TG2 (see Clinical antibody tests), levels of CXCL11
protein were below the 80% CR of the group with
active CD and thus corresponded to the “Not CD” group
(Additional file 2).
One of the two CD cases with remaining enteropathy
on a GFD that were misclassified based on anti-TG2 (see
Clinical antibody tests) showed a level of the TNFRSF9
mRNA marker for normalized CD (Figure 1) that was
below the 80% CR of the group with normalized CD3A 3B 3C
or Marsh grades 0 (n = 25), 1 (n = 7), 2 (n = 1), 3A (n = 8), 3B (n = 6), and









































Figure 3 Antibody levels vs. Marsh grade. Antibody/autoantibody levels in serum/plasma against A) tissue transglutaminase (anti-TG2), B)
deamidated gliadin (anti-DGP), and C) gliadin (anti-GL) vs. Marsh grade (0-3C) on a logarithmic scale. Open circles represent cases without a celiac
disease (CD) diagnosis, open squares represent CD cases on a gluten-free diet, filled squares represent CD cases on a gluten-containing diet, and
filled triangles represent cases under investigation for suspected CD. The dotted line represents the cut-off threshold for a positive result indicative
of CD.
Bragde et al. BMC Gastroenterology 2014, 14:176 Page 6 of 9
http://www.biomedcentral.com/1471-230X/14/176and within the 80% CR for the group with active CD
(Additional file 2).
The remaining results fell within the 80% CR for more
than one group.
Cases included in the group under investigation (Table 1,
Under investigation) were on a gluten-containing diet and
under continuous monitoring for suspected CD. Consid-
ering markers CXCL11 protein and TNFSF13B mRNA,
the median of the group fell within the 80% CR for both
the group without a CD diagnosis and the group with
active CD (Additional file 2).
ROC curve analysis
ROC curve analysis of discrimination between cases with
active CD and without CD (Figure 4A and B) revealed a
larger area under the curve (AUC) for anti-TG2 (AUC =
0.97) in comparison to CXCL11 protein (AUC = 0.81),
TNFSF13B mRNA (AUC = 0.85), and a logistic regres-
sion model based on CXCL11 protein and TNFSF13B
mRNA (AUC = 0.91). A logistic regression model based
on anti-TG2, CXCL11 protein, and TNFSF13B mRNAFigure 4 Receiver operating characteristic (ROC) curves. ROC curve an
and without CD (A and B) or between cases with active CD and normalize
TNFSF13B messenger RNA (mRNA) (dashed line), and a logistic regression m
in (B) correspond to tissue transglutaminase autoantibodies (anti-TG2) (soli
TNFSF13B mRNA (dashed line). ROC curves in (C) correspond to anti-TG2 (s
of anti-TG2 and TNFRSF9 mRNA (dotted line).resulted in the highest AUC (0.98). However, compared
to anti-TG2 alone, this improvement was not significant
(p = 0.54). ROC curve analysis of discrimination between
cases with active CD and normalized CD (Figure 4C) re-
vealed an AUC of 0.90 for anti-TG2 and 0.78 for TNFRSF9
mRNA. Compared to anti-TG2 alone, a logistic regression
model based on anti-TG2 and TNFRSF9 mRNA resulted
in an increased AUC of 0.93 (p = 0.54).
Discussion
The prospect of a blood-based diagnostic procedure for
CD is appealing. This is reflected by the new recommen-
dations from ESPGHAN, which offer the option to omit
biopsies in patients with anti-TG2 titers of 10 times
ULN or more [14]. In patients with high pretest prob-
ability for CD in combination with anti-TG2 levels of 10
times ULN or more, the probability of having CD is high,
but it decreases somewhat in patients with lower pretest
probabilities [22]. All patients with anti-TG2 levels of 10
times ULN or more in the current study were diagnosed
with CD. However, in patients with lower antibody levelsalysis of discrimination between cases with active celiac disease (CD)
d CD (C). ROC curves in (A) correspond to CXCL11 protein (solid line),
odel of CXCL11 protein and TNFSF13B mRNA (dotted line). ROC curves
d line) and a logistic regression model of anti-TG2, CXCL11 protein, and
olid line), TNFRSF9 mRNA (dashed line), and a logistic regression model
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nostics seem to be less clear-cut [23,24], and additional
blood-based CD markers could be useful. Three potential
blood-based CD markers (CXCL11 protein, TNFRSF9
mRNA, and TNFSF13B mRNA) were identified in the
current study.
CXCL11 protein, which is an IFN-γ and IFN-β induced
chemokine [25], and mRNA from TNFSF13B, which en-
codes a cytokine with a major role in B cell growth and
survival [26], showed elevated levels in cases with active
CD compared to cases without a CD diagnosis, which is
consistent with previous studies of CXCL11 mRNA in
small intestinal biopsies [15,27] and TNFSF13B in serum
[28]. An increased level of TNFSF13B mRNA was also
evident in cases with CD and normalized histology
compared to cases without a CD diagnosis, which is also
consistent with previous results [28]. Increased serum
levels of TNFSF13B protein have previously been found
in autoimmune diseases [26], and CXCL11 has also been
implicated in autoimmune diseases [29].
CXCL11 protein level correlated significantly with
Marsh grade, as did mRNA levels of IL21, which is in-
volved in the control of the innate and adaptive immune
responses [30], and IL15, which is involved in the innate
immune response in CD [31].
A decreased level of mRNA from TNFRSF9, which is a
receptor induced on the surface of CD4+ and CD8+ T
cells during activation [32], was found in cases with ac-
tive CD and in cases without a CD diagnosis, compared
with CD cases with normalized histology. This result dif-
fers from that in small intestinal biopsies [15], indicating
tissue-specific regulation.
Potentially, CXCL11 protein, TNFRSF9 mRNA, and
TNFSF13B mRNA might assist in the clinical diagnosis
of CD. The established blood-based CD marker anti-
TG2 misclassified one case with active CD and two cases
without enteropathy on a gluten-containing diet, and
two cases with remaining enteropathy on a GFD. In
cases on a gluten-containing diet, CXCL11 protein
showed the greatest potential as a marker, with results
in accordance with histopathology for two out of three
cases misclassified by anti-TG2. For cases on a GFD with
remaining enteropathy, results for TNFRSF9 mRNA were
in accordance with histopathology for one out of two
cases.
ROC curve analysis showed that, as a single test, the
already established anti-TG2 assay outperformed the
new potential blood-based CD markers. However, it
might be possible to increase the diagnostic performance
by considering several assay results jointly. Adding new
markers to the anti-TG2 assay produced a slight, though
non-significant, increase in diagnostic performance. At
present, the data is too limited for any firm conclusions
regarding added diagnostic value, and our analysisprovided no suggestions as to the potential CD status of
cases in the group under investigation.
Several proteins in serum/plasma have previously been
suggested as potential blood-based CD markers, for
example regenerating gene Iα protein and intestinal fatty
acid binding protein [33,34]. Recently, Galatola et al.
proposed a discriminant model based on the expression
of four genes including REL and TNFAIP3 [35], which
along with TNFSF13B and TNFRSF9 (identified as po-
tential CD markers in the current study) are involved in
regulation of the NF-κB complex [32,36,37]. Further-
more, the NF-κB complex is involved in the IFN-β in-
duced transcription of CXCL11 [38], and REL is involved
in the transcriptional activation of TNFSF13B [26]. This
indicates that additional investigations into NF-κB inter-
acting proteins could reveal new potential markers for
diagnosis and monitoring of CD.
Conclusions
The CD markers identified in this study further emphasize
the significance of components related to NF-κB regula-
tion in relation to CD. However, the diagnostic relevance
of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB inter-
acting proteins recognized by pathway analysis needs to
be further investigated.
Human genes
The human genes discussed in this article are presented
in Additional file 1.
Additional files
Additional file 1: Genes selected for messenger RNA (mRNA) and/
or protein detection in human blood. Protein/mRNA levels were
investigated in cases with active celiac disease (CD), cases with confirmed
CD and normalized histology, cases without a CD diagnosis, and cases
under investigation for suspected CD. Some genes were selected based
on their context; others were selected based on information from
published studies.
Additional file 2: Descriptive data on differentially expressed
potential blood-based celiac disease (CD) markers. Study subjects are
divided into groups depending on the diagnosis and the histopathologic
assessment.
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